Angana A. H. Patel

Angana A. H. Patel

Auto-generated profile, based on publicly available information

Angana A. H. Patel

Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2026 in Nature
Verified
Journal Article
Open access
APAngana A. H. Patel
Angana A. H. Patel
JDJozefina J. Dzanan
Jozefina J. Dzanan
KAKevin X. Ali
Kevin X. Ali
Ella EklundElla Eklund
Ella Eklund
SASamantha W. Alvarez
Samantha W. Alvarez
VSVolkan Sayin
Volkan Sayin
Lung cancer predominantly affects older individuals, yet how physiological ageing influences tumour evolution remains poorly understood 1 . Here we show that ageing reprograms the evolutionary trajectory of KRAS -driven lung adenocarcinoma, limiting primary tumour growth while promoting metastatic dissemination through epigenetic activation of the integrated stress response (ISR). The ISR effector ATF4 drives epithelial and metabolic plasticity, conferring metastatic competence. Mechanistically, aged tumour cells show increased sensitivity to the PERK–eIF2α arm of the unfolded protein response, sustaining persistent ATF4 signalling. Targeting ISR–ATF4 genetically or pharmacologically abolishes these adaptations and limits dissemination, whereas ATF4 overexpression alone is sufficient to induce metastasis. The ageing–ATF4 axis imposes a dependency on glutamine metabolism, revealing a therapeutically actionable vulnerability. Clinical analyses confirm that ATF4 is enriched in aged tumours and correlates with poor survival and advanced-stage disease. Collectively, these results define epigenetic ISR–ATF4 activation as a causal driver of lineage plasticity and metastasis in aged tumours, revealing a therapeutic opportunity in older patients with lung adenocarcinoma, the most common yet understudied subset of lung cancer.

6 November 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JCJaroslaw Cisowski
Jaroslaw Cisowski
Ahmed Ezat El ZowalatyAhmed Ezat El Zowalaty
Ahmed Ezat El Zowalaty
SSSama I. Sayin
Sama I. Sayin
PCPiotr Czarnota
Piotr Czarnota
TGTomasz Gromowski
Tomasz Gromowski
MBMartin Bergo
Martin Bergo
The MEK–ERK pathway is a key driver of hepatocellular carcinoma (HCC) pathogenesis, and BRAF mutations, particularly BRAF V600E , can contribute to its activation. Although BRAF V600E mutations are rare in human HCC, they do occur, yet their physiologic impact in liver cells, especially when combined with frequent comutations in tumor suppressor genes, remains poorly understood. Moreover, the effect of BRAF inhibitors on HCC progression and metastasis is not well-defined. Therefore, we developed mouse models with hepatocyte-specific BRAF V600E expression and Trp53 or Cdkn2a deletion to assess tumor development, subtypes, and metastatic patterns. We found that BRAF V600E expression caused hepatomegaly, vascular congestion, and ductal reactions, and led to reduced liver function and early mortality. Codeletion of Trp53 or Cdkn2a markedly increased primary liver tumor incidence and enabled sarcomatoid metastasis. While the BRAF inhibitor PLX4720 effectively reduced primary tumors and extended survival, it paradoxically increased sarcomatoid metastases. Mechanistically, PLX4720 and other RAF inhibitors induced TGFβ2 expression which promoted epithelial-to-mesenchymal transition (EMT) and enhanced tumorigenicity. The effects of RAF inhibitors on TGFβ2 expression were validated in BRAF V600E -mutant human melanoma cells. We conclude that BRAF V600E drives diverse primary tumors but only one type of metastasis and that RAF inhibition, while effective against primary tumors, may promote metastasis through TGFβ2-mediated EMT. Although RAF inhibitors remain promising therapies, their unintended role in enhancing metastasis raises concerns that may extend beyond liver cancer to other BRAF V600E -driven malignancies.